title: Distinctive features of the D101N and D101G variants of superoxide dismutase 1; two mutations that produce rapidly progressing motor neuron disease.
abstract: Mutations in superoxide dismutase 1 (SOD1) associated with familial amyotrophic lateral sclerosis induce misfolding and aggregation of the protein with the inherent propensity of mutant SOD1 to aggregate generally correlating, with a few exceptions, to the duration of illness in patients with the same mutation. One notable exception was the D101N variant, which has been described as wild-type-like. The D101N mutation is associated with rapidly progressing motor neuron degeneration but shows a low propensity to aggregate. By assaying the kinetics of aggregation in a well-characterized cultured cell model, we show that the D101N mutant is slower to initiate aggregation than the D101G mutant. In this cell system of protein over-expression, both mutants were equally less able to acquire Zn than WT SOD1. In addition, both of these mutants were equivalently less able to fold into the trypsin-resistant conformation that characterizes WT SOD1. A second major difference between the two mutants was that the D101N variant more efficiently formed a normal intramolecular disulfide bond. Overall, our findings demonstrate that the D101N and D101G variants exhibit clearly distinctive features, including a different rate of aggregation, and yet both are associated with rapidly progressing disease. We sought to better characterize the biochemical features of two SOD1 mutants associated with rapidly progressing disease, the D101G and wild-type like D101N mutants. We observed using our cell model that that although similarities were observed when comparing the ability to bind metals and resist trypsin digestion, these mutants differed in their ability to initiate aggregation and to form the normal intramolecular disulfide bond. We conclude that these mutants exhibit distinct properties despite producing similar disease phenotypes in patients.
authors.affiliation: Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
authors.forename: Jacob
authors.initials: J
authors.lastname: Ayers
authors.forename: Herman
authors.initials: H
authors.lastname: Lelie
authors.forename: Aron
authors.initials: A
authors.lastname: Workman
authors.forename: Mercedes
authors.initials: M
authors.lastname: Prudencio
authors.forename: Hilda
authors.initials: H
authors.lastname: Brown
authors.forename: Susan
authors.initials: S
authors.lastname: Fromholt
authors.forename: Joan
authors.initials: J
authors.lastname: Valentine
authors.forename: Julian
authors.initials: J
authors.lastname: Whitelegge
authors.forename: David
authors.initials: D
authors.lastname: Borchelt
mesh_terms: D057809:HEK293 Cells; D006801:Humans; D016472:Motor Neuron Disease / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D009154:Mutation; D017510:Protein Folding; D013482:Superoxide Dismutase / Q000235:genetics* / Q000378:metabolism; D000072105:Superoxide Dismutase-1; D015032:Zinc / Q000378:metabolism
chemical_list: C000606290:SOD1 protein, human; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D015032:Zinc
keywords: ALS; SOD1; aggregation; oxidation; stability
references.citation: J Neurochem. 2009 Feb;108(4):1009-18
references.pmid: 19077113
references.citation: J Neurochem. 2012 May;121(3):475-85
references.pmid: 22332887
references.citation: J Biol Chem. 2008 May 16;283(20):13528-37
references.pmid: 18316367
references.citation: Antioxid Redox Signal. 2009 Jul;11(7):1603-14
references.pmid: 19271992
references.citation: Hum Mol Genet. 1999 Aug;8(8):1451-60
references.pmid: 10400992
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10516-21
references.pmid: 16020530
references.citation: Neurobiol Dis. 2000 Dec;7(6 Pt B):623-43
references.pmid: 11114261
references.citation: Hum Mol Genet. 2003 Nov 1;12(21):2753-64
references.pmid: 12966034
references.citation: J Biol Chem. 2008 Aug 29;283(35):24167-76
references.pmid: 18552350
references.citation: Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14157-62
references.pmid: 17715066
references.citation: Cell Mol Life Sci. 2003 Jul;60(7):1281-95
references.pmid: 12943218
references.citation: J Biol Chem. 2004 Dec 24;279(52):54558-66
references.pmid: 15485869
references.citation: Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8292-6
references.pmid: 8058797
references.citation: Neurobiol Dis. 2005 Dec;20(3):943-52
references.pmid: 16046140
references.citation: Mol Neurodegener. 2011 Nov 17;6:77
references.pmid: 22094223
references.citation: J Biol Chem. 2010 Jun 18;285(25):19544-52
references.pmid: 20189984
references.citation: Science. 1998 Sep 18;281(5384):1851-4
references.pmid: 9743498
references.citation: Hum Mol Genet. 2010 Dec 15;19(24):4774-89
references.pmid: 20871097
references.citation: J Biol Chem. 2011 Jan 28;286(4):2795-806
references.pmid: 21068388
references.citation: Neurobiol Dis. 1998 Jul;5(1):27-35
references.pmid: 9702785
references.citation: EMBO J. 2007 Feb 7;26(3):855-66
references.pmid: 17255946
references.citation: J Biol Chem. 2007 Jul 20;282(29):21230-6
references.pmid: 17513298
references.citation: Hum Mol Genet. 2009 Sep 1;18(17):3217-26
references.pmid: 19483195
references.citation: Proc Natl Acad Sci U S A. 2009 May 12;106(19):7774-9
references.pmid: 19416874
references.citation: Brain. 2006 Feb;129(Pt 2):451-64
references.pmid: 16330499
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18663-8
references.pmid: 19022905
references.citation: J Biol Chem. 1995 Feb 17;270(7):3234-8
references.pmid: 7852409
references.citation: J Am Chem Soc. 2007 Apr 18;129(15):4575-83
references.pmid: 17381088
references.citation: Neurobiol Dis. 2001 Dec;8(6):933-41
references.pmid: 11741389
references.citation: Neurology. 1997 Jul;49(1):213-22
references.pmid: 9222193
references.citation: Proc Natl Acad Sci U S A. 2006 May 2;103(18):7142-7
references.pmid: 16636275